Literature DB >> 23479259

Assessing bleeding risk in patients taking anticoagulants.

Marwa Shoeb1, Margaret C Fang.   

Abstract

Anticoagulant medications are commonly used for the prevention and treatment of thromboembolism. Although highly effective, they are also associated with significant bleeding risks. Numerous individual clinical factors have been linked to an increased risk of hemorrhage, including older age, anemia, and renal disease. To help quantify hemorrhage risk for individual patients, a number of clinical risk prediction tools have been developed. These risk prediction tools differ in how they were derived and how they identify and weight individual risk factors. At present, their ability to effective predict anticoagulant-associated hemorrhage remains modest. Use of risk prediction tools to estimate bleeding in clinical practice is most influential when applied to patients at the lower spectrum of thromboembolic risk, when the risk of hemorrhage will more strongly affect clinical decisions about anticoagulation. Using risk tools may also help counsel and inform patients about their potential risk for hemorrhage while on anticoagulants, and can identify patients who might benefit from more careful management of anticoagulation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23479259      PMCID: PMC3888359          DOI: 10.1007/s11239-013-0899-7

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  39 in total

1.  Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants.

Authors:  Margaret C Fang; Alan S Go; Yuchiao Chang; Leila H Borowsky; Niela K Pomernacki; Natalia Udaltsova; Daniel E Singer
Journal:  Stroke       Date:  2012-04-26       Impact factor: 7.914

2.  Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy.

Authors:  C S Landefeld; L Goldman
Journal:  Am J Med       Date:  1989-08       Impact factor: 4.965

3.  Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls.

Authors:  M Man-Son-Hing; G Nichol; A Lau; A Laupacis
Journal:  Arch Intern Med       Date:  1999-04-12

4.  Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall.

Authors:  Brian F Gage; Elena Birman-Deych; Roger Kerzner; Martha J Radford; David S Nilasena; Michael W Rich
Journal:  Am J Med       Date:  2005-06       Impact factor: 4.965

5.  Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism.

Authors:  P M Kuijer; B A Hutten; M H Prins; H R Büller
Journal:  Arch Intern Med       Date:  1999-03-08

6.  A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy.

Authors:  G Palareti; C Legnani; A Lee; C Manotti; J Hirsh; A D'Angelo; V Pengo; M Moia; S Coccheri
Journal:  Thromb Haemost       Date:  2000-11       Impact factor: 5.249

7.  Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin.

Authors:  R J Beyth; L M Quinn; C S Landefeld
Journal:  Am J Med       Date:  1998-08       Impact factor: 4.965

8.  Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients.

Authors:  Theresa I Shireman; Patricia A Howard; Timothy F Kresowik; Edward F Ellerbeck
Journal:  Stroke       Date:  2004-08-26       Impact factor: 7.914

9.  Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis.

Authors:  Lori-Ann Linkins; Peter T Choi; James D Douketis
Journal:  Ann Intern Med       Date:  2003-12-02       Impact factor: 25.391

10.  Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation.

Authors:  Margaret C Fang; Yuchiao Chang; Elaine M Hylek; Jonathan Rosand; Steven M Greenberg; Alan S Go; Daniel E Singer
Journal:  Ann Intern Med       Date:  2004-11-16       Impact factor: 25.391

View more
  58 in total

1.  Incidence and endovascular treatment of severe spontaneous non-cerebral bleeding: a single-institution experience.

Authors:  Stavros Spiliopoulos; Georgios Festas; Antonios Theodosis; Konstantinos Palialexis; Lazaros Reppas; Chysostomos Konstantos; Elias Brountzos
Journal:  Eur Radiol       Date:  2018-12-05       Impact factor: 5.315

Review 2.  Predicting the risk of recurrent venous thromboembolism (VTE).

Authors:  Michael B Streiff
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

3.  In vitro hemodynamic assessment of a novel polymeric transcatheter aortic valve.

Authors:  Megan Heitkemper; Hoda Hatoum; Lakshmi Prasad Dasi
Journal:  J Mech Behav Biomed Mater       Date:  2019-06-19

Review 4.  Advances in Biomaterials and Technologies for Vascular Embolization.

Authors:  Jingjie Hu; Hassan Albadawi; Brian W Chong; Amy R Deipolyi; Rahul A Sheth; Ali Khademhosseini; Rahmi Oklu
Journal:  Adv Mater       Date:  2019-06-06       Impact factor: 30.849

Review 5.  Review of numerical methods for simulation of mechanical heart valves and the potential for blood clotting.

Authors:  Mohamad Shukri Zakaria; Farzad Ismail; Masaaki Tamagawa; Ahmad Fazli Abdul Aziz; Surjatin Wiriadidjaja; Adi Azrif Basri; Kamarul Arifin Ahmad
Journal:  Med Biol Eng Comput       Date:  2017-07-26       Impact factor: 2.602

6.  Development of a Controlled Vocabulary-Based Adverse Drug Reaction Signal Dictionary for Multicenter Electronic Health Record-Based Pharmacovigilance.

Authors:  Suehyun Lee; Jongsoo Han; Rae Woong Park; Grace Juyun Kim; John Hoon Rim; Jooyoung Cho; Kye Hwa Lee; Jisan Lee; Sujeong Kim; Ju Han Kim
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

Review 7.  Effects of therapeutic plasma exchange on anticoagulants in patients receiving therapeutic anticoagulation: a systematic review.

Authors:  Kimberly L Hodulik; Adam G Root; Leila S Ledbetter; Oluwatoyosi A Onwuemene
Journal:  Transfusion       Date:  2019-02-14       Impact factor: 3.157

8.  Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.

Authors:  Zachary Howe; Chad Naville-Cook; Derek Cole
Journal:  J Thromb Thrombolysis       Date:  2019-02       Impact factor: 2.300

Review 9.  [Procedures on patients receiving NOACs : What's possible?]

Authors:  A Polzin; M Kelm; P Horn
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-01-10       Impact factor: 0.840

10.  Mortality among patients due to adverse drug reactions that occur following hospitalisation: a meta-analysis.

Authors:  Parvati B Patel; Tejas K Patel
Journal:  Eur J Clin Pharmacol       Date:  2019-06-11       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.